Clinical-pathological Characterization and Outcomes of Renal Cell Carcinoma in Latin American

Latin American Cooperative Oncology Group211 enrolled

Overview

Observational study, retrospective and prospective, of an analytical nature. Data will be collected from medical records and/or through contact with physicians and institutions (secondary data collection). Patients included retrospectively or prospectively will be followed during the data collection period for the evaluation of treatments and survival. No intervention is planned in this protocol.

Study Type

OBSERVATIONAL

Enrollment

211

Conditions

Kidney Neoplasms

Interventions

Observational studyOTHER

This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients ≥ 18 years of age; * Proven histology of renal cell carcinoma (any subtype); * Pathological diagnosis of renal cell carcinoma in January 2015 or later and new cases diagnosed during the period of recruitment of each center; * Have the medical record available and suitable for collecting data on patient characteristics, treatment and outcome. Exclusion Criteria: * Synchronous or other primary tumor within the last 3 years (except thyroid cancer or non melanoma skin).

Locations (16)

CINPAM - Centro Integrado de Pesquisa da Amazônia

Manaus, Amazonas, Brazil

Oncocentro Ceará (Rede D'or)

Fortaleza, Ceará, Brazil

Outcomes

Primary Outcomes

Build a real-life renal cell cancer database in Brazil and Latin America

Time frame: 2022

Secondary Outcomes

Sociodemographic characteristics checklist

Describe sociodemographic characteristics: age at diagnosis, race, education, family income, occupation, personal habits, family history, comorbidities, treatment funding (public or private), treatment institution (public, private or philanthropic).

Time frame: 2022

Clinicopathological characteristics of patients with renal cell cancer checklist

date of onset of symptoms, pre-treatment symptoms, histology, clinical and pathological stage, performance status, tests used in staging, date of diagnosis, site of metastases, complications clinics.

Time frame: 2022

Characteristics of systemic treatment checklist

date of biopsy; dates, type and lines of drug treatment.

Time frame: 2022

Time between diagnosis and start of treatment.

Characteristics of systemic treatment checklist

Time frame: 2022

Causes of delay or discontinuation of each treatment checklist

Characteristics of systemic treatment

Time frame: 2022

Progression-free survival in each therapeutic line

Time frame: 2022

Overall survival

Time frame: 2022

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.